At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GNLX Genelux Corporation
Trading 11-22 14:44:24 EST
2.47
+0.01
+0.45%
High2.55
Low2.40
Vol177.01K
Open2.53
D1 Closing2.46
Amplitude6.09%
Mkt Cap84.27M
Tradable Cap63.67M
Total Shares34.10M
T/O437.66K
T/O Rate0.69%
Tradable Shares25.77M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Genelux Corp’s Strategic Advances in Cancer Trials Position GNLX as a Promising Investment
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.